Stockreport

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biolo [Read more]